The Equal Employment Opportunity Commission (EEOC) has filed a lawsuit against Bollinger Shipyards, alleging the company unlawfully excluded job applicants from safety-sensitive positions due to their lawful use of a prescription medication for opioid use disorder. The lawsuit centers on the company\u2019s zero-tolerance policy regarding Suboxone, a medication approved by the U.S. Food and Drug Administration (FDA) for treating addiction, and marks a significant legal test of how the Americans with Disabilities Act (ADA) applies to employers\u2019 drug screening practices in high-stakes industrial roles. According to the EEOC, Bollinger Shipyards disqualified as many as five candidates from the hiring process solely because they were taking Suboxone as prescribed, a move the agency argues constitutes illegal discrimination based on a perceived disability.<\/p>\n
The EEOC\u2019s complaint details a systematic screening practice by Bollinger Shipyards, a major marine fabrication and ship repair company headquartered in Louisiana. The company, which operates facilities across the Gulf Coast, allegedly maintained a blanket ban on applicants who tested positive for buprenorphine, the active ingredient in Suboxone, regardless of whether the individual had a valid prescription and was using the medication as directed by a physician. This practice, the EEOC contends, violates the ADA because it treated these applicants as having a disability\u2014namely, a history of or current treatment for substance use disorder\u2014and then denied them employment based on that treatment, rather than on their actual ability to perform the essential functions of the job.<\/p>\n
The five unidentified applicants had reportedly progressed through various stages of the application process, including interviews and skill assessments, only to be removed from consideration after failing a drug test that revealed the presence of Suboxone. The EEOC asserts that none of these individuals were provided an individualized assessment of their capacity to work safely in a shipyard environment, which can involve operating heavy machinery, working at heights, and handling hazardous materials. Instead, the company applied a rigid policy that effectively preempted any consideration of medical documentation or professional judgment regarding the compatibility of the medication with workplace safety.<\/p>\n
Suboxone is a brand-name prescription medication that combines buprenorphine and naloxone. It is primarily used in medication-assisted treatment (MAT) for opioid use disorder, helping to manage withdrawal symptoms and reduce cravings. Under the ADA, individuals who are taking such medication as part of a supervised treatment program are generally protected from discrimination, provided they are not currently using illegal drugs. The EEOC has long held that a person participating in a lawful MAT program is protected under the ADA, and that employers must conduct individualized assessments before disqualifying such an individual from a job, even a safety-sensitive one.<\/p>\n
The legal contention in this specific suit rests on whether Bollinger Shipyards had a legitimate, job-related reason for its blanket ban. The company operates in an industry where safety is paramount\u2014a single lapse can lead to catastrophic injury or loss of life. However, the EEOC\u2019s position is that a categorical exclusion based on a medication\u2019s presence in a drug test is not a valid safety justification. The agency argues that the employer did not evaluate whether the specific dosage or the individual\u2019s response to the medication actually impaired their ability to work. Without such an evaluation, the EEOC asserts, the policy amounts to a presumption of incompetence or dangerousness, which is precisely the type of stereotyping the ADA was designed to prevent. This case could set a major precedent for how courts interpret the balance between employer safety concerns and the rights of employees in recovery under federal law.<\/p>\n
For employers across the country, particularly those in manufacturing, transportation, and energy sectors, the ADA requires a careful navigation of health information and safety requirements. The law does not prevent an employer from requiring a drug test or from excluding a person who is currently engaging in the illegal use of drugs. However, it draws a sharp distinction for individuals who are lawfully using a prescribed medication as part of a treatment program. In such cases, the employer\u2019s obligation is to determine whether the individual poses a \u201cdirect threat\u201d to the health or safety of themselves or others that cannot be eliminated by reasonable accommodation.<\/p>\n
This \u201cdirect threat\u201d standard is not a low bar. It requires an employer to conduct an individualized assessment based on objective evidence, not on generalizations or assumptions about a particular disability or treatment. The assessment must consider factors such as the duration of the risk, the nature and severity of the potential harm, the likelihood that the harm will occur, and the imminence of the harm. In the Bollinger Shipyards case, the EEOC is expected to argue that the company failed to meet any of these standards by simply relying on a positive drug screen result. The agency\u2019s lawsuit seeks back pay, compensatory damages, and injunctive relief, meaning a court order requiring Bollinger to revise its hiring policies and provide training to prevent future violations.<\/p>\n
The lawsuit signals that the EEOC is actively scrutinizing employer drug testing policies that disproportionately impact individuals in recovery from substance use disorder. For any company operating in a safety-sensitive field, the key requirement is to move away from blanket prohibitions based on medication presence alone. Instead, employers must have a process in place to verify lawful prescriptions, consult with medical professionals about the potential impact of the medication on specific job duties, and consider reasonable accommodations. A policy that automatically disqualifies an applicant for testing positive for a legally prescribed medication like Suboxone, without any attempt at individualized assessment, is the exact target of this enforcement action. This serves as a clear warning that \u201czero-tolerance\u201d drug policies, while popular in high-risk industries, must be carefully calibrated to comply with federal disability law.<\/p>\n
Bollinger Shipyards is not a small operation. With facilities in Louisiana, Texas, and Mississippi, the company has been a pillar of the Gulf Coast maritime industry for decades, constructing and repairing vessels for commercial, military, and government clients, including the U.S. Coast Guard and the U.S. Navy. Its workforce includes welders, pipefitters, electricians, mechanics, and riggers\u2014all positions that involve significant physical demands, complex machinery, and inherent risks. The company\u2019s own safety protocols are extensive, and it has long maintained a drug-free workplace policy that includes pre-employment, random, and post-accident testing.<\/p>\n
The EEOC\u2019s suit challenges the specific implementation of that policy, not the policy itself. Few would argue against the need for drug testing in environments where errors can have lethal consequences. The dispute is about the granularity of the rule. By eliminating candidates without investigating the facts of their medical treatment, Bollinger may have exposed itself to liability not only for the five named applicants but for a broader class of individuals who may have been similarly excluded. This case has the potential to force a significant procedural change in how the company manages medical information obtained through its screening processes.<\/p>\n
The outcome of this case will be closely monitored by human resources and legal departments in industries ranging from oil and gas extraction to commercial aviation and nuclear power. Many of these sectors have adopted strict drug testing panels that routinely screen for buprenorphine without a mechanism for medical review. A ruling against Bollinger Shipyards would compel many of these employers to re-evaluate their pre-employment testing protocols. It would also likely accelerate the trend\u2014already in motion at some Fortune 500 companies\u2014of separating the forensic process of drug screening from the employment decision, allowing for a medical review officer to evaluate prescriptions before a rejection is issued.<\/p>\n
The case also has implications for the broader conversation about the opioid crisis in America. For years, stigma surrounding medication-assisted treatment has created additional barriers for individuals seeking to re-enter the workforce, particularly in high-paying industrial jobs. A loss for Bollinger Shipyards would be a significant victory for advocates of MAT, affirming that participation in a doctor-supervised recovery program cannot be used as a basis for employment discrimination. Conversely, a win for the company could embolden other industrial firms to maintain or even tighten restrictions on prescribed medications, potentially chilling the willingness of employees to seek treatment.<\/p>\n
For organizations with safety-sensitive positions, the EEOC\u2019s action serves as a concrete operational directive. The first step is a review of current drug screening policies with legal counsel to ensure they include a clear path for an individualized medical assessment. This process typically involves engaging a medical review officer (MRO) who can contact the applicant\u2019s prescribing physician to confirm the validity of the prescription, discuss the dosage and potential side effects, and determine if any work restrictions are medically necessary. Based on that information, the employer must then decide if there is a direct threat that cannot be addressed through reasonable accommodation.<\/p>\n
A reasonable accommodation for an individual taking Suboxone in a shipyard might be a temporary restriction from operating specific machinery, a change in shift schedule to avoid fatigue, or a verification that the current dosage is stable and does not cause sedation. The accommodation cannot be an undue hardship on the employer, and it must be determined through a collaborative process with the individual. The EEOC\u2019s case against Bollinger Shipyards underscores that skipping this entire step is not just a poor hiring practice\u2014it is a violation of federal law.<\/p>\n
This lawsuit is also a prominent example of the EEOC\u2019s renewed focus under its current strategic enforcement plan, which specifically identifies discrimination against individuals with opioid use disorder as a priority. The agency has issued public guidance and brought several high-profile cases in recent years, arguing that the ADA\u2019s protections extend to people taking medication as part of a supervised recovery plan. The Bollinger case is among the most consequential because of the stark conflict it presents: an industry where safety is genuinely non-negotiable facing a legal mandate to look past a medical treatment that still carries social stigma.<\/p>\n
The lawsuit could also influence state-level employment law. Several states have already enacted laws that restrict employers from discriminating against individuals who use lawful medications, including those used in MAT. A strong federal ruling in this case would provide a uniform baseline, reducing the patchwork of compliance burdens for national employers and offering clearer protections for workers in recovery.<\/p>\n
As this case proceeds through the U.S. District Court for the Eastern District of Louisiana, it will serve as a high-profile test of how far the duty of individualized assessment extends. For now, the message from the EEOC is unequivocal: a drug test is not a substitute for a conversation, and a prescription is not a firing offense. The final judgment will not only affect the five applicants who were denied work but will likely reshape the boundaries between medical privacy, workplace safety, and employment opportunity for years to come. Companies in all high-risk industries would be wise to treat this litigation not as a distant legal dispute, but as a direct call to audit their own policies before they become the subject of the next EEOC complaint.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Equal Employment Opportunity Commission (EEOC) has filed a lawsuit against Bollinger Shipyards, alleging the company unlawfully excluded job applicants from safety-sensitive positions due to their lawful use of a prescription medication for opioid use disorder. The lawsuit centers on the company\u2019s zero-tolerance policy regarding Suboxone, a medication approved by the U.S. Food and Drug […]<\/p>\n","protected":false},"author":11,"featured_media":98806,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/cards.overcentral.com\/cards\/en\/98802.png","fifu_image_alt":"EEOC Sues Bollinger Shipyards over Suboxone Ban for Safety-Sensitive","footnotes":""},"categories":[40791],"tags":[],"class_list":["post-98802","post","type-post","status-publish","format-standard","has-post-thumbnail","category-management"],"fifu_image_url":"https:\/\/cards.overcentral.com\/cards\/en\/98802.png","fifu_image_alt":"EEOC Sues Bollinger Shipyards over Suboxone Ban for Safety-Sensitive","_links":{"self":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts\/98802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/comments?post=98802"}],"version-history":[{"count":1,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts\/98802\/revisions"}],"predecessor-version":[{"id":98807,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/posts\/98802\/revisions\/98807"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/media\/98806"}],"wp:attachment":[{"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/media?parent=98802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/categories?post=98802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/overcentral.com\/en\/wp-json\/wp\/v2\/tags?post=98802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}